CoChat
Sign Up
Cited by 99

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Targeted Oral Delivery of Paclitaxel Using Colostrum-Derived Exosomes

Kandimalla, Raghuram, Aqil, Farrukh, Alhakeem, Sara, Jeyabalan, Jeyaprakash, Tyagi, Neha, Agrawal, Ashish, Yan, Jun, Spencer, Wendy, Bondada, Subbarao, Gupta, Ramesh·2021·Cancers
DOI 10.3390/cancers13153700PMC PMC8345039
Open this paper in CoChat — free account

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) is the most common type accounting for 84% of all lung cancers. Paclitaxel (PAC) is a widely used drug in the treatment of a broad spectrum of human cancers, including lung. While efficacious, PAC generally is not well tolerated and its limitations include low aqueous solubility, and significant toxicity. To overcome the dose-related toxicity of solvent-based PAC, we utilized bovine colostrum-derived exosomes as a delivery vehicle for PAC for the treatment of lung cancer. Colostrum provided higher yield of exosomes and could be loaded with higher amount of PAC compared to mature milk. Exosomal formulation of PAC (ExoPAC) showed higher antiproliferative activity and inhibition of colony formation against A549 cells compared with PAC alone, and also showed antiproliferative activity against a drug-resistant variant of A549. To further enhance its efficacy, exosomes were attached with a tumor-targeting ligand, folic acid (FA). FA-ExoPAC given orally showed significant inhibition (>50%) of subcutaneous tumor xenograft while similar doses of PAC showed insignificant inhibition. In the orthotopic lung cancer model, oral dosing of FA-ExoPAC achieved greater efficacy (55% growth inhibition) than traditional i.v. PAC (24–32% growth inhibition) and similar efficacy as i.v. Abraxane (59% growth inhibition). The FA-ExoPAC given i.v. exceeded the therapeutic efficacy of Abraxane (76% growth inhibition). Finally, wild-type animals treated with p.o. ExoPAC did not show gross, systemic or immunotoxicity. Solvent-based PAC caused immunotoxicity which was either reduced or completely mitigated by its exosomal formulations. These studies show that a tumor-targeted oral formulation of PAC (FA-ExoPAC) significantly improved the overall efficacy and safety profile while providing a user-friendly, cost-effective alternative to bolus i.v. PAC and i.v. Abraxane.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13153700

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization and drug loading of colostrum-derived exosomes. Size, polydispersity index (PDI), and zeta potential (ZP) of exosomes, FA-Exo, ExoPAC and FA-ExoPAC, analyzed by Zetasizer. Data represent mean ± SD from three preparations (A). Analysis of exosomes and ExoPAC by atomic force microscopy (AFM) after diluting with deionized water up to 10 μg/mL. For measurement, samples were placed on a silica wafer and air-dried for 30 min. AFM in tapping mode and aluminum-coated silicon probes were used for imaging (B). The bar diagram shows the quenching of autofluorescence from the exosomes following PAC loading (C). Higher quenching of fluorescence in the presence of higher drug load suggests a hydrophobic interaction of drug with exosomal proteins.
Figure 1 Characterization and drug loading of colostrum-derived exosomes. Size, polydispersity index (PDI), and zeta potential (ZP) of exosomes, FA-Exo, ExoPAC and FA-ExoPAC, analyzed by Zetasizer. Data represent mean ± SD from three preparations (A). Analysis of exosomes and ExoPAC by atomic force microscopy (AFM) after diluting with deionized water up to 10 μg/mL. For measurement, samples were placed on a silica wafer and air-dried for 30 min. AFM in tapping mode and aluminum-coated silicon probes were used for imaging (B). The bar diagram shows the quenching of autofluorescence from the exosomes following PAC loading (C). Higher quenching of fluorescence in the presence of higher drug load suggests a hydrophobic interaction of drug with exosomal proteins.CC BY · PubMed Central
Figure 2 ExoPAC inhibits proliferation of drug-sensitive and drug-resistant cells. (A) Drug-sensitive (A549) and drug-resistant (A549TR) cells were treated with Exo, ExoPAC and FA-ExoPAC and compared with Abraxane. Antiproliferative activity was determined by MTT assay after 72 h. Exosomal PAC dose-dependently inhibited the proliferation of drug-sensitive A549 (A) and drug-resistant A549TR cells (B).
Figure 2 ExoPAC inhibits proliferation of drug-sensitive and drug-resistant cells. (A) Drug-sensitive (A549) and drug-resistant (A549TR) cells were treated with Exo, ExoPAC and FA-ExoPAC and compared with Abraxane. Antiproliferative activity was determined by MTT assay after 72 h. Exosomal PAC dose-dependently inhibited the proliferation of drug-sensitive A549 (A) and drug-resistant A549TR cells (B).CC BY · PubMed Central
Figure 3 Exosomal PAC inhibited colony formation in NSCLC cells. Representative images showing the colony formation assay in drug-sensitive A549 (A) and drug-resistant A549TR (B) cells. Lung cancer cells were seeded (500 cells/well) in a six-well plate and incubated with different concentrations of PAC and ExoPAC. After 10 days, developed colonies were fixed, stained and counted manually. While PAC was effective, only against drug-sensitive cells (A1,B1), ExoPAC shows dose-dependent inhibition of colony formation of both sensitive and resistant cells (A2,B2). Statistical analysis was performed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 3 Exosomal PAC inhibited colony formation in NSCLC cells. Representative images showing the colony formation assay in drug-sensitive A549 (A) and drug-resistant A549TR (B) cells. Lung cancer cells were seeded (500 cells/well) in a six-well plate and incubated with different concentrations of PAC and ExoPAC. After 10 days, developed colonies were fixed, stained and counted manually. While PAC was effective, only against drug-sensitive cells (A1,B1), ExoPAC shows dose-dependent inhibition of colony formation of both sensitive and resistant cells (A2,B2). Statistical analysis was performed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY · PubMed Central
Figure 4 Antitumor activity against subcutaneous xenografts. Following inoculation with A549 cells, nude mice were treated with oral gavage three times a week with PAC (6 mg/kg bw), ExoPAC and FA-ExoPAC (6 mg PAC and 50 mg Exo protein/kg bw). Data represent average ± SD of means (n = 8). Statistical analysis was performed using the Student’s t-test. * p < 0.05; ** p < 0.01.
Figure 4 Antitumor activity against subcutaneous xenografts. Following inoculation with A549 cells, nude mice were treated with oral gavage three times a week with PAC (6 mg/kg bw), ExoPAC and FA-ExoPAC (6 mg PAC and 50 mg Exo protein/kg bw). Data represent average ± SD of means (n = 8). Statistical analysis was performed using the Student’s t-test. * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 5 Antitumor activity against orthotopic xenografts. Detection of orthotopic lung cancer using bioluminescent A549-Red-luc cells. (A) A1: image of live animals after 27 d of inoculation with 2 × 106 cells (3 mice/group). A2: Mean of bioluminescence signals. (B) Inhibition of A549 orthotopic lung tumors in NOD Scid female mice (n = 10) by i.v. paclitaxel (PAC), i.v. Abraxane, and p.o. ExoPAC and p.o. FA-ExoPAC (three doses weekly), all given at 6 mg/kg. FA-Exo was used as control for FA-ExoPAC. (C) Inhibition of A549 orthotopic lung tumors in NOD Scid female mice (n = 10) by i.v. PAC, Abraxane, FA-ExoPAC (once weekly) and p.o. ExoPAC and FA-ExoPAC (three doses weekly), all given at 4 mg/kg until three wks, then switched to 8 mg/kg, as indicated by an arrow in C2. Representative images of animals at different time points in the indicated treatment groups (C1) and time-dependent tumor inhibition (C2). Statistical analysis was performed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 5 Antitumor activity against orthotopic xenografts. Detection of orthotopic lung cancer using bioluminescent A549-Red-luc cells. (A) A1: image of live animals after 27 d of inoculation with 2 × 106 cells (3 mice/group). A2: Mean of bioluminescence signals. (B) Inhibition of A549 orthotopic lung tumors in NOD Scid female mice (n = 10) by i.v. paclitaxel (PAC), i.v. Abraxane, and p.o. ExoPAC and p.o. FA-ExoPAC (three doses weekly), all given at 6 mg/kg. FA-Exo was used as control for FA-ExoPAC. (C) Inhibition of A549 orthotopic lung tumors in NOD Scid female mice (n = 10) by i.v. PAC, Abraxane, FA-ExoPAC (once weekly) and p.o. ExoPAC and FA-ExoPAC (three doses weekly), all given at 4 mg/kg until three wks, then switched to 8 mg/kg, as indicated by an arrow in C2. Representative images of animals at different time points in the indicated treatment groups (C1) and time-dependent tumor inhibition (C2). Statistical analysis was performed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY · PubMed Central
Figure 6 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Live splenic (A) and bone marrow (B) cell counts were performed by trypan blue exclusion.
Figure 6 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Live splenic (A) and bone marrow (B) cell counts were performed by trypan blue exclusion.CC BY · PubMed Central
Figure 7 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Splenic cells were stained with multiple fluorochrome-conjugated antibodies. Samples were run using LSRII cytometer and data was analyzed by FlowJo software. Effect of treatment was analyzed on B cells, total T-cells, T helper cells, and cytotoxic T-cells (A), macrophages, neutrophils and dendritic cells (B), B cell (C), %LSK cells (D) and T-cell proliferation (E). All statistical analysis was performed by two-way ANOVA and compared with untreated control. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 7 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Splenic cells were stained with multiple fluorochrome-conjugated antibodies. Samples were run using LSRII cytometer and data was analyzed by FlowJo software. Effect of treatment was analyzed on B cells, total T-cells, T helper cells, and cytotoxic T-cells (A), macrophages, neutrophils and dendritic cells (B), B cell (C), %LSK cells (D) and T-cell proliferation (E). All statistical analysis was performed by two-way ANOVA and compared with untreated control. *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY · PubMed Central
Figure 8 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Splenic cells were treated with the different stimulant for 24 h. Sups were collected and MesoScale analysis (V-PLEX of 6 cytokines) was performed. LPS was used for B-cell response and αCD3+αCD28 for T-cell response. All statistical analysis was performed by two-way ANOVA and compared with untreated control. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 8 Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Splenic cells were treated with the different stimulant for 24 h. Sups were collected and MesoScale analysis (V-PLEX of 6 cytokines) was performed. LPS was used for B-cell response and αCD3+αCD28 for T-cell response. All statistical analysis was performed by two-way ANOVA and compared with untreated control. *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Siegel, 2021, Cancer Statistics, 2021, CA Cancer J. Clin., 71, 7
  2. Siegel, 2014, Cancer statistics, 2014, CA Cancer J. Clin., 64, 9
  3. Horwitz, 1994, Taxol (paclitaxel): Mechanisms of action, Ann. Oncol., 5, S3
  4. Constantinides, 2000, Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel, Pharm. Res., 17, 175, 10.1023/A:1007565230130 · DOI
  5. Sarpotdar, 1996, Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res., 13, 272, 10.1023/A:1016051316815 · DOI
  6. Palumbo, 2015, Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: Prospective evaluation of activity, safety, and quality of life, Drug Des. Dev. Ther., 9, 2189, 10.2147/DDDT.S79563 · DOI
  7. Chou, 2020, Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis, Int. J. Nanomed., 15, 1731, 10.2147/IJN.S231407 · DOI
  8. Kooijmans, 2012, Exosome mimetics: A novel class of drug delivery systems, Int. J. Nanomed., 7, 1525
  9. Lakhal, 2011, Exosome nanotechnology: An emerging paradigm shift in drug delivery: Exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers, Bioessays, 33, 737, 10.1002/bies.201100076 · DOI · Paper page
  10. Aisner, 2007, Overview of the changing paradigm in cancer treatment: Oral chemotherapy, Am. J. Health Syst. Pharm., 64, S4, 10.2146/ajhp070035 · DOI
  11. Joo, 2008, Oral paclitaxel chemotherapy for brain tumors: Ideal combination treatment of paclitaxel and P-glycoprotein inhibitor, Oncol. Rep., 19, 17
  12. Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 60, 1878
  13. Bobrie, 2011, Exosome secretion: Molecular mechanisms and roles in immune responses, Traffic, 12, 1659, 10.1111/j.1600-0854.2011.01225.x · DOI
  14. Kandimalla, 2021, Milk exosomes: A biogenic nanocarrier for small molecules and macromolecules to combat cancer, Am. J. Reprod. Immunol., 85, e13349, 10.1111/aji.13349 · DOI
  15. Vader, 2016, Extracellular vesicles for drug delivery, Adv. Drug Deliv. Rev., 106, 148, 10.1016/j.addr.2016.02.006 · DOI · Paper page
  16. Agrawal, 2017, Milk-derived exosomes for oral delivery of paclitaxel, Nanomed. Nanotechnol. Biol. Med., 13, 1627, 10.1016/j.nano.2017.03.001 · DOI
  17. Aqil, 2017, Exosomal delivery of berry anthocyanidins for the management of ovarian cancer, Food Funct., 8, 4100, 10.1039/C7FO00882A · DOI
  18. Munagala, 2017, Exosomal formulation of anthocyanidins against multiple cancer types, Cancer Lett., 393, 94, 10.1016/j.canlet.2017.02.004 · DOI
  19. Aqil, 2016, Exosomal formulation enhances therapeutic response of celastrol against lung cancer, Exp. Mol. Pathol., 101, 12, 10.1016/j.yexmp.2016.05.013 · DOI
  20. Aqil, 2019, Milk exosomes—Natural nanoparticles for siRNA delivery, Cancer Lett., 449, 186, 10.1016/j.canlet.2019.02.011 · DOI
  21. Munagala, 2021, Exosome-mediated delivery of RNA and DNA for gene therapy, Cancer Lett., 505, 58, 10.1016/j.canlet.2021.02.011 · DOI
  22. Yang, 2013, Insights into the binding of paclitaxel to human serum albumin: Multispectroscopic studies, Lumin. J. Biol. Chem. Lumin., 28, 427, 10.1002/bio.2522 · DOI
  23. Kyakulaga, 2020, Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells, Oncotarget, 11, 1399, 10.18632/oncotarget.27519 · DOI
  24. Fan, 2011, Stable isotope resolved metabolomics of lung cancer in a SCID mouse model, Metab. Off. J. Metab. Soc., 7, 257
  25. Zhong, 2009, Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models, J. Immunother., 32, 703, 10.1097/CJI.0b013e3181ad3fcf · DOI
  26. Umanzor, G., Rugo, H.S., Barrios, F.J., Vasallo, R.H., Chivalan, M.A., Bejarano, S., Ramirez, J.R., Fein, L., Kowalyszyn, R.D., and Cutler, D.L. (2020, January 8–11). Abstract PD1-08: Oral Paclitaxel and Encequidar (oPac + E) versus IV paclitaxel (IVPac) in the Treatment of Metastatic Breast Cancer (mBC) Patients (Study KX-ORAX-001): Progression Free Survival (PFS) and Overall Survival (OS) Updates. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA. · DOI
  27. Rugo, H.S., Umanzor, G., Barrios, F.J., Vasallo, R.H., Chivalan, M.A., Bejarano, S., Ramirez, J.R., Fein, L., Kowalyszyn, R.D., and Cutler, D.L. (2020, January 8–11). Lower Rates of Neuropathy with Oral Paclitaxel and Encequidar (oPac + E) Compared to IV Paclitaxel (IVPac) in Treatment of Metastatic Breast Cancer (mBC): Study KX-ORAX-001. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA.
  28. Mendt, M., Kamerkar, S., Sugimoto, H., McAndrews, K.M., Wu, C.C., Gagea, M., Yang, S., Blanko, E.V.R., Peng, Q., and Ma, X. (2018). Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight., 3. · DOI
  29. Ledermann, 2015, Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments, Ann. Oncol., 26, 2034, 10.1093/annonc/mdv250 · DOI
  30. Shi, 2015, A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer, Drug Des. Dev. Ther., 9, 4989
  31. Cheung, 2016, Targeting folate receptor alpha for cancer treatment, Oncotarget, 7, 52553, 10.18632/oncotarget.9651 · DOI · Paper page
  32. Low, 2009, Folate-targeted therapeutic and imaging agents for cancer, Curr. Opin. Chem. Biol., 13, 256, 10.1016/j.cbpa.2009.03.022 · DOI
  33. Sega, 2008, Tumor detection using folate receptor-targeted imaging agents, Cancer Metastasis Rev., 27, 655, 10.1007/s10555-008-9155-6 · DOI
  34. Morelli, 2004, Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells, Blood, 104, 3257, 10.1182/blood-2004-03-0824 · DOI
  35. Aqil, 2017, Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin, AAPS J., 19, 1691, 10.1208/s12248-017-0154-9 · DOI
  36. Parolini, 2009, Microenvironmental pH is a key factor for exosome traffic in tumor cells, J. Biol. Chem., 284, 34211, 10.1074/jbc.M109.041152 · DOI
  37. Feng, 2010, Cellular internalization of exosomes occurs through phagocytosis, Traffic, 11, 675, 10.1111/j.1600-0854.2010.01041.x · DOI
  38. Killion, 1998, Orthotopic models are necessary to predict therapy of transplantable tumors in mice, Cancer Metastasis Rev., 17, 279, 10.1023/A:1006140513233 · DOI
  39. Kerbel, 2003, Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved, Cancer Biol. Ther., 2, S134, 10.4161/cbt.213 · DOI
  40. Fauzee, 2011, Taxanes: Promising Anti-Cancer Drugs, Asian Pac. J. Cancer Prev., 12, 837

Cited by

Sorted by citations

See all 99

Metadata

Authors
Kandimalla, R., Aqil, F., Alhakeem, S., Jeyabalan, J., Tyagi, N., Agrawal, A., Yan, J., Spencer, W., Bondada, S., & Gupta, R.
Venue
Cancers
Publisher
MDPI AG
Published
2021-07-23
Volume
13
Issue
15
Pages
3700
ISSN
2072-6694
DOI
10.3390/cancers13153700
PMC
PMC8345039
Cited by
99
References
3
Language
en
Update notices
correction (2021-07-23)
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Institutes of Health (R44-CA-221487)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review